Elucida Oncology nabs more funds for its take on ADCs, sees potential in radiotherapy partnership

Elu­ci­da On­col­o­gy has raised an­oth­er ap­prox­i­mate­ly $30 mil­lion to bring its ver­sion of an­ti­body-drug con­ju­gates to more pa­tients in the clin­i­cal set­ting, the com­pa­ny told End­points News.

The CDC has a dif­fer­ent mean­ing over at the New Jer­sey biotech, which is de­vel­op­ing what it calls “C’Dot-Drug-Con­ju­gates.” The goal is to bet­ter at­tack can­cer­ous tis­sue with small­er-sized nanopar­ti­cles, more po­ten­cy and less ad­verse im­pact on pa­tients’ health. Elu­ci­da’s take on the class of AD­Cs, which have bal­looned in R&D pop­u­lar­i­ty and sur­passed the dozen mile­stone in terms of reg­u­la­to­ry ap­provals, start­ed in the labs of Cor­nell and has gone through fur­ther de­vel­op­ment at Memo­r­i­al Sloan Ket­ter­ing. The com­pa­ny came to­geth­er a lit­tle un­der a decade ago, per SEC fil­ings.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN